OpenLB
Open Library of Bioscience
Advanced Search
Methods in molecular biology (Clifton, N.J.)
2023;2663 253-262.

An Overview of Laboratory Testing for Antiphospholipid Antibodies.

Emmanuel J Favaloro, Leonardo Pasalic
Author Information
  1. Emmanuel J Favaloro: School of Medical Sciences, Faculty of Medicine and Health University of Sydney, Westmead Hospital, Westmead, NSW, Australia. Emmanuel.Favaloro@health.nsw.gov.au. ORCID
  2. Leonardo Pasalic: Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia. ORCID
PMID: 37204715 DOI: 10.1007/978-1-0716-3175-1_15

Abstract

Antiphospholipid antibodies (aPL) represent a group of autoantibodies directed against phospholipids. These antibodies may arise in a number of autoimmune conditions, of which the antiphospholipid (antibody) syndrome (APS) is best recognized. aPL can be detected by various laboratory assays, essentially comprising both solid-phase (immunological) assays and "liquid-phase" clotting assays identifying so-called lupus anticoagulants (LA). aPL are associated with various adverse pathologies, including thrombosis and placental/fetal morbidity and mortality. The type of aPL present, as well as the pattern of reactivity, is variously associated with the severity of the pathology. Thus, laboratory testing for aPL is indicated to help assess the future risk of such events, as well as representing certain "classification" criteria for APS, also used as surrogates for diagnostic criteria. The current chapter overviews the laboratory tests available to measure aPL and their potential clinical utility.

Keywords

APS Antiphospholipid (antibody) syndrome Antiphospholipid antibodies Diagnostics Laboratory testing Lupus anticoagulant aPL

References

  1. Wong RCW, Favaloro EJ (2008) Clinical features, diagnosis and management of the antiphospholipid syndrome. Semin Thromb Hemost 34:295–304. https://doi.org/10.1055/s-0028-1082275 . PMID: 18720311 [DOI: 10.1055/s-0028-1082275]
  2. Favaloro EJ, Wong RCW (2009) Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey. Pathology 41:666–675. https://doi.org/10.3109/00313020903257731 [DOI: 10.3109/00313020903257731]
  3. Favaloro EJ, Wong RCW (2010) The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours? Autoimmun Highlights 1:5–14. https://doi.org/10.1007/s13317-010-0003-7 [DOI: 10.1007/s13317-010-0003-7]
  4. Favaloro EJ, Wong RCW (2014) Antiphospholipid antibody testing for the antiphospholipid syndrome: a synopsis of challenges and recent guidelines. Pathology 46(6):481–495. https://doi.org/10.1097/PAT.0000000000000142 [DOI: 10.1097/PAT.0000000000000142]
  5. Tincani A, Bazzani C, Zingarelli S, Lojacono A (2008) Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost 34(3):267–273. https://doi.org/10.1055/s-0028-1082270 [DOI: 10.1055/s-0028-1082270]
  6. Hunt BJ (2008) Pediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 34(3):274–281. https://doi.org/10.1055/s-0028-1082271 [DOI: 10.1055/s-0028-1082271]
  7. Miesbach W (2008) Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost 34(3):282–285. https://doi.org/10.1055/s-0028-1082272 [DOI: 10.1055/s-0028-1082272]
  8. Miesbach W (2008) Neurologic symptoms as a feature of the antiphospholipid syndrome. Semin Thromb Hemost 34(3):286–289. https://doi.org/10.1055/s-0028-1082273 [DOI: 10.1055/s-0028-1082273]
  9. Espinosa G, Bucciarelli S, Asherson RA, Cervera R (2008) Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost 34(3):290–294. https://doi.org/10.1055/s-0028-1082274 [DOI: 10.1055/s-0028-1082274]
  10. Sacharidou A, Shaul PW, Mineo C (2018) New insights in the pathophysiology of antiphospholipid syndrome. Semin Thromb Hemost 44(5):475–482. https://doi.org/10.1055/s-0036-1597286 [DOI: 10.1055/s-0036-1597286]
  11. Wong RCW, Favaloro EJ (2008) A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays. Semin Thromb Hemost 34(4):361–372. https://doi.org/10.1055/s-0028-1085479 [DOI: 10.1055/s-0028-1085479]
  12. Favaloro EJ, Wong RCW (2008) Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost 34(4):389–410. https://doi.org/10.1055/s-0028-1085482 [DOI: 10.1055/s-0028-1085482]
  13. Favaloro EJ, Wong R (2011) Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 49(3):447–461. https://doi.org/10.1515/CCLM.2011.064 [DOI: 10.1515/CCLM.2011.064]
  14. Pierangeli S, Groot P, Dlott J et al (2011) ‘Criteria’ aPL tests: report of a task force and preconference workshop at the 13th international congress on antiphospholipid antibodies, Galveston, Texas, April 2010. Lupus 20(2):182–190. https://doi.org/10.1177/0961203310395055 [DOI: 10.1177/0961203310395055]
  15. Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, Pierangeli SS (2012) International consensus guidelines on anticardiolipin and anti-β(2) glycoprotein I testing: report from the APL task force at the 13(th) international congress on antiphospholipid antibodies. Arthritis Rheum 64(1):1–10. https://doi.org/10.1002/art.33349 [DOI: 10.1002/art.33349]
  16. Pierangeli SS, Favaloro EJ, Lakos G, Meroni PL, Tincani A, Wong RC, Harris EN (2012) Standards and reference materials for the anticardiolipin and anti-β(2)glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta 413(1–2):358–360. https://doi.org/10.1016/j.cca.2011.09.048 [DOI: 10.1016/j.cca.2011.09.048]
  17. Favaloro EJ, Reben R, Mohammed S, Koutts J (2012) Clinical audit of antiphospholipid antibody testing in tertiary practice. Towards improved relevance in thrombophilia investigations? Intern Med J 42(4):427–434. https://doi.org/10.1111/j.1445-5994.2010.02329.x [DOI: 10.1111/j.1445-5994.2010.02329.x]
  18. Devreese KMJ, de Groot PG, de Laat B et al (2020) Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 18(11):2828–2839. https://doi.org/10.1111/jth.15047 [DOI: 10.1111/jth.15047]
  19. Wong R, Adelstein S, Gillis D, Favaloro EJ (2005) Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing. Semin Thromb Hemost 31(1):39–48. https://doi.org/10.1055/s-2005-863804 [DOI: 10.1055/s-2005-863804]
  20. Galli M (2008) Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome. Semin Thromb Hemost 34(4):329–334. https://doi.org/10.1055/s-0028-1085474 [DOI: 10.1055/s-0028-1085474]
  21. Gris JC, Brenner B (2013) Antiphospholipid antibodies: neuropsychiatric presentations. Semin Thromb Hemost 39(8):935–942. https://doi.org/10.1055/s-0033-1357488 [DOI: 10.1055/s-0033-1357488]
  22. Tufano A, Di Minno MND, Guida A, Lembo M, Di Minno G, Galderisi M (2019) Cardiac manifestations of antiphospholipid syndrome: clinical presentation, role of cardiac imaging, and treatment strategies. Semin Thromb Hemost 45(5):468–477. https://doi.org/10.1055/s-0039-1692702 [DOI: 10.1055/s-0039-1692702]
  23. Antovic A, Bruzelius M (2021) Impaired fibrinolysis in the antiphospholipid syndrome. Semin Thromb Hemost 47(5):506–511. https://doi.org/10.1055/s-0041-1725098 [DOI: 10.1055/s-0041-1725098]
  24. Álvarez D, Rúa C, Cadavid JÁP (2021) Microparticles: an alternative explanation to the behavior of vascular antiphospholipid syndrome. Semin Thromb Hemost 47(7):787–799. https://doi.org/10.1055/s-0041-1727111 [DOI: 10.1055/s-0041-1727111]
  25. Ames PRJ, Bucci T, Iannaccone L, Marottoli V, Arcaro A, Gentile F, Ciampa A (2019) Validity of coagulation activation markers in antiphospholipid syndrome: a systematic review and meta-analysis with a short data report. Semin Thromb Hemost 45(5):458–467. https://doi.org/10.1055/s-0039-1692701 [DOI: 10.1055/s-0039-1692701]
  26. Aibar J, Schulman S (2021) Arterial thrombosis in patients with antiphospholipid syndrome: a review and meta-analysis. Semin Thromb Hemost 47(6):709–723. https://doi.org/10.1055/s-0041-1725057 [DOI: 10.1055/s-0041-1725057]
  27. Schreiber K, Hunt BJ (2016) Pregnancy and antiphospholipid syndrome. Semin Thromb Hemost 42(7):780–788. https://doi.org/10.1055/s-0036-1592336 [DOI: 10.1055/s-0036-1592336]
  28. Lim W (2014) Thrombotic risk in the antiphospholipid syndrome. Semin Thromb Hemost 40(7):741–746. https://doi.org/10.1055/s-0034-1390003 [DOI: 10.1055/s-0034-1390003]
  29. Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78(9):1151–1159. https://doi.org/10.1136/annrheumdis-2018-214819 [DOI: 10.1136/annrheumdis-2018-214819]
  30. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x [DOI: 10.1111/j.1538-7836.2006.01753.x]
  31. Bertolaccini ML, Sanna G (2018) The clinical relevance of noncriteria antiphospholipid antibodies. Semin Thromb Hemost 44(5):453–457. https://doi.org/10.1055/s-0037-1601328 [DOI: 10.1055/s-0037-1601328]
  32. Devreese KMJ (2023) Laboratory testing for non-criteria antiphospholipid antibodies – antiphosphatidylserine/prothrombin antibodies (aPS/PT). In: Favaloro EJ, Gosselin RC (eds) Hemostasis and thrombosis: methods and protocols, Methods in molecular biology. Springer, New York, pp 315–327. https://doi.org/10.1007/978-1-0716-3175-1_20
  33. Devreese KMJ (2023) Laboratory testing for non-criteria antiphospholipid antibodies – antibodies towards the domain one of beta2-glycoprotein I (aDI). In: Favaloro EJ, Gosselin RC (eds) Hemostasis and thrombosis: methods and protocols, Methods in molecular biology. Springer, New York, pp 329–340. https://doi.org/10.1007/978-1-0716-3175-1_21
  34. Willis R, Papalardo E, Nigel Harris E (2017) Solid phase immunoassay for the detection of anti-β(2) glycoprotein I antibodies. Methods Mol Biol 1646:201–215. https://doi.org/10.1007/978-1-4939-7196-1_17 [DOI: 10.1007/978-1-4939-7196-1_17]
  35. Willis R, Papalardo E, Nigel HE (2017) Solid phase immunoassay for the detection of anticardiolipin antibodies. Methods Mol Biol 1646:185–199. https://doi.org/10.1007/978-1-4939-7196-1_16 [DOI: 10.1007/978-1-4939-7196-1_16]
  36. Favaloro EJ, Mohammed S, Vong R, Pasalic L (2023) Antiphospholipid antibody testing for anti-cardiolipin and anti-β2Glycoprotein I antibodies using chemiluminescence-based panels. In: Favaloro EJ, Gosselin RC (eds) Hemostasis and thrombosis: methods and protocols, Methods in molecular biology. Springer, New York, pp 297–314. https://doi.org/10.1007/978-1-0716-3175-1_19
  37. Kelchtermans H, Chayouâ W, Laat B (2018) The significance of antibodies against domain I of Beta-2 glycoprotein I in antiphospholipid syndrome. Semin Thromb Hemost 44(5):458–465. https://doi.org/10.1055/s-0037-1601329 [DOI: 10.1055/s-0037-1601329]
  38. Oku K, Atsumi T, Amengual O, Koike T (2008) Antiprothrombin antibody testing: detection and clinical utility. Semin Thromb Hemost 34(4):335–339 [DOI: 10.1055/s-0028-1085475]
  39. Radin M, Cecchi I, Roccatello D, Meroni PL, Sciascia S (2018) Prevalence and thrombotic risk assessment of anti-β2 glycoprotein I domain I antibodies: a systematic review. Semin Thromb Hemost 44(5):466–474. https://doi.org/10.1055/s-0037-1603936 [DOI: 10.1055/s-0037-1603936]
  40. Pengo V, Tripodi A, Reber G, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7(10):1737–1740. https://doi.org/10.1111/j.1538-7836.2009.03555.x [DOI: 10.1111/j.1538-7836.2009.03555.x]
  41. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, British Committee for Standards in Haematology (2012) Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 157(1):47–58. https://doi.org/10.1111/j.1365-2141.2012.09037.x [DOI: 10.1111/j.1365-2141.2012.09037.x]
  42. Arachchillage DRJ, Gomez K, Alikhan R, Anderson JAM, Lester W, Laffan M, British Society for Haematology Haemostasis and Thrombosis Taskforce (2020) Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br J Haematol 157:47–58): use of direct acting oral anticoagulants. Br J Haematol 189(2):212–215. https://doi.org/10.1111/bjh.16308 [DOI: 10.1111/bjh.16308]
  43. Clinical and Laboratory Standards Institute (CLSI) (2014) Laboratory testing for the lupus anticoagulant; approved guideline, CLSI document H60-A. CLSI, Wayne
  44. Moore GW (2014) Commonalities and contrasts in recent guidelines for lupus anticoagulant detection. Int J Lab Hematol 36(3):364–373. https://doi.org/10.1111/ijlh.12227 . PMID: 24750683 [DOI: 10.1111/ijlh.12227]
  45. Moore GW (2014) Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 40(2):163–171. https://doi.org/10.1055/s-0033-1364185 [DOI: 10.1055/s-0033-1364185]
  46. Favaloro EJ, Mohammed S, Vong R et al (2022) A multi-laboratory assessment of lupus anticoagulant assays performed on the ACL TOP 50 family for harmonized testing in a large laboratory network. Int J Lab Hematol 44(3):654–665. https://doi.org/10.1111/ijlh.13818 [DOI: 10.1111/ijlh.13818]
  47. Tripodi A, Chantarangkul V (2017) Lupus anticoagulant testing: Activated Partial Thromboplastin Time (APTT) and Silica Clotting Time (SCT). Methods Mol Biol 1646:177–183. https://doi.org/10.1007/978-1-4939-7196-1_15 [DOI: 10.1007/978-1-4939-7196-1_15]
  48. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S (2005) Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 93(6):1147–1152. https://doi.org/10.1160/TH04-12-0839 [DOI: 10.1160/TH04-12-0839]
  49. Szabó G, Antal-Szalmás P, Kerényi A, Pénzes K, Bécsi B, Kappelmayer J (2022) Laboratory approaches to test the function of antiphospholipid antibodies. Semin Thromb Hemost 48(2):132–144. https://doi.org/10.1055/s-0041-1730357 [DOI: 10.1055/s-0041-1730357]
  50. Favaloro EJ, Plebani M, Lippi G (2014) Standardization and harmonization of antiphospholipid antibody assays. Semin Thromb Hemost 40(2):161–162. https://doi.org/10.1055/s-0033-1364184 [DOI: 10.1055/s-0033-1364184]
  51. Favaloro EJ (2013) Trials and tribulations in lupus anticoagulant testing. Clin Chem Lab Med 51(2):253–256. https://doi.org/10.1515/cclm-2012-0578 [DOI: 10.1515/cclm-2012-0578]
  52. de Groot PG, Derksen RH, de Laat B (2008) Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. Semin Thromb Hemost 34(4):347–355. https://doi.org/10.1055/s-0028-1085477 [DOI: 10.1055/s-0028-1085477]
  53. Andreoli L, Rizzini S, Allegri F, Meroni P, Tincani A (2008) Are the current attempts at standardization of antiphospholipid antibodies still useful? Emerging technologies signal a shift in direction. Semin Thromb Hemost 34(4):356–360. https://doi.org/10.1055/s-0028-1085478 [DOI: 10.1055/s-0028-1085478]
  54. Willis R, Lakos G, Harris EN (2014) Standardization of antiphospholipid antibody testing-historical perspectives and ongoing initiatives. Semin Thromb Hemost 40(2):172–177. https://doi.org/10.1055/s-0033-1364207 [DOI: 10.1055/s-0033-1364207]
  55. Bonar R, Favaloro EJ, Zebeljan D, Rosenfeld D, Kershaw G, Mohammed S, Marsden K, Hertzberg M (2012) Evaluating laboratory approaches to the identification of lupus anticoagulants: a diagnostic challenge from the RCPA Haematology QAP. Pathology 44(3):240–247. https://doi.org/10.1097/PAT.0b013e32834d7b83 [DOI: 10.1097/PAT.0b013e32834d7b83]
  56. Favaloro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RCW (2012) Internal quality control and external quality assurance in testing for antiphospholipid antibodies: part I – anti-cardiolipin and anti-β2-glycoprotein I antibodies. Semin Thromb Hemost 38(4):390–403. https://doi.org/10.1055/s-0032-1311990 [DOI: 10.1055/s-0032-1311990]
  57. Favaloro EJ, Bonar R, Marsden K (2012) Internal quality control and external quality assurance in testing for antiphospholipid antibodies: part II – lupus anticoagulant. Semin Thromb Hemost 38(4):404–411. https://doi.org/10.1055/s-0032-1311993 [DOI: 10.1055/s-0032-1311993]
  58. Favaloro EJ (2013) Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants. Int J Lab Hematol 35(3):269–274. https://doi.org/10.1111/ijlh.12072 [DOI: 10.1111/ijlh.12072]
  59. Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K (2010) Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 8(12):2828–2831. https://doi.org/10.1111/j.1538-7836.2010.04090.x [DOI: 10.1111/j.1538-7836.2010.04090.x]
  60. Favaloro EJ, Bonar R, Marsden K (2013) Lupus anticoagulant testing – sometimes mixing is required: potential for false negatives without mixing studies. Blood Coagul Fibrinolysis 24(6):673–676. https://doi.org/10.1097/MBC.0b013e328360c71b [DOI: 10.1097/MBC.0b013e328360c71b]
  61. Favaloro EJ (2020) Point – mixing studies for lupus anticoagulant: mostly yes, sometimes no. Clin Chem Lab Med 58(4):487–491. https://doi.org/10.1515/cclm-2019-1240 [DOI: 10.1515/cclm-2019-1240]
  62. Moore GW (2020) Mixing studies for lupus anticoagulant: mostly no, sometimes yes. Clin Chem Lab Med 58(4):492–495. https://doi.org/10.1515/cclm-2019-1248 [DOI: 10.1515/cclm-2019-1248]
  63. Favaloro EJ (2020) Coagulation mixing studies: utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests. Am J Hematol 95(1):117–128. https://doi.org/10.1002/ajh.25669 [DOI: 10.1002/ajh.25669]
  64. Tripodi A (2008) Laboratory testing for lupus anticoagulants: diagnostic criteria and use of screening, mixing, and confirmatory studies. Semin Thromb Hemost 34(4):373–379. https://doi.org/10.1055/s-0028-1085480 [DOI: 10.1055/s-0028-1085480]
  65. Ledford-Kraemer MR (2008) Laboratory testing for lupus anticoagulants: pre-examination variables, mixing studies, and diagnostic criteria. Semin Thromb Hemost 34(4):380–388. https://doi.org/10.1055/s-0028-1085481 [DOI: 10.1055/s-0028-1085481]
  66. Kershaw G, Suresh S, Orellana D, Nguy YM (2012) Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 38(4):375–384. https://doi.org/10.1055/s-0032-1311991 [DOI: 10.1055/s-0032-1311991]
  67. Tripodi A (2012) To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost 38(4):385–389. https://doi.org/10.1055/s-0032-1304717 [DOI: 10.1055/s-0032-1304717]
  68. Pengo V, Bison E, Denas G, Jose SP, Bracco A, Banzato A (2014) The paradox of the lupus anticoagulant: history and perspectives. Semin Thromb Hemost 40(8):860–865. The paradox of the lupus anticoagulant: history and perspectives [DOI: 10.1055/s-0034-1395158]
  69. Molhoek JE, de Groot PG, Urbanus RT (2018) The lupus anticoagulant paradox. Semin Thromb Hemost 44(5):445–452. https://doi.org/10.1055/s-0037-1606190 [DOI: 10.1055/s-0037-1606190]
  70. Thachil J (2021) Doctor, do I have lupus? Time to reconsider the lupus anticoagulant terminology. Semin Thromb Hemost 47(7):892–894. https://doi.org/10.1055/s-0041-1728787 [DOI: 10.1055/s-0041-1728787]
  71. Favaloro EJ, Kershaw G, Mohammed S, Lippi G (2019) How to optimize Activated Partial Thromboplastin Time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. Semin Thromb Hemost 45(1):22–35. https://doi.org/10.1055/s-0038-1677018 [DOI: 10.1055/s-0038-1677018]
  72. Kershaw G (2017) Performance of Activated Partial Thromboplastin Time (APTT): determining reagent sensitivity to factor deficiencies, heparin, and lupus anticoagulants. Methods Mol Biol 1646:75–83. https://doi.org/10.1007/978-1-4939-7196-1_5 [DOI: 10.1007/978-1-4939-7196-1_5]
  73. Favaloro EJ (2019) The Russell Viper Venom Time (RVVT) test for investigation of lupus anticoagulant (LA). Am J Hematol 94(11):1290–1296. https://doi.org/10.1002/ajh.25606 [DOI: 10.1002/ajh.25606]
  74. Favaloro EJ, Mohammed S, Curnow J, Pasalic L (2019) Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. Pathology 51(3):292–300. https://doi.org/10.1016/j.pathol.2018.11.008 [DOI: 10.1016/j.pathol.2018.11.008]
  75. Favaloro EJ, Gilmore G, Arunachalam S, Mohammed S, Baker R (2019) Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): a comparative study using DOAC Stop and andexanet alfa. Thromb Res 180:10–19. https://doi.org/10.1016/j.thromres.2019.05.013 [DOI: 10.1016/j.thromres.2019.05.013]
  76. Arachchillage DJ, Crossette-Thambiah C, Laffan M (2022) Lupus anticoagulant and cardiopulmonary bypass. Semin Thromb Hemost 48(5):628–630. https://doi.org/10.1055/s-0042-1750045 [DOI: 10.1055/s-0042-1750045]
  77. Favaloro EJ, Pasalic L (2022) Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants. Res Pract Thromb Haemost 6(2):e12676. https://doi.org/10.1002/rth2.12676 [DOI: 10.1002/rth2.12676]
  78. Exner T, Ahuja M, Ellwood L (2019) Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants. Clin Chem Lab Med 57(5):690–696. https://doi.org/10.1515/cclm-2018-0967 [DOI: 10.1515/cclm-2018-0967]
  79. Exner T, Rigano J, Favaloro EJ (2020) The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays. Int J Lab Hematol 42(Suppl 1):41–48. https://doi.org/10.1111/ijlh.13196 [DOI: 10.1111/ijlh.13196]
  80. Gosselin RC (2021) Review of coagulation preanalytical variables with update on the effect of direct oral anticoagulants. Int J Lab Hematol 43(Suppl 1):109–116. https://doi.org/10.1111/ijlh.13585 [DOI: 10.1111/ijlh.13585]
  81. Favaloro EJ, Henry BM, Lippi G (2022) COVID-19 and antiphospholipid antibodies: time for a reality check? Semin Thromb Hemost 48(1):72–92. https://doi.org/10.1055/s-0041-1728832 [DOI: 10.1055/s-0041-1728832]
  82. Favaloro EJ, Henry BM, Lippi G (2022) Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 48(1):55–71. https://doi.org/10.1055/s-0041-1729856 [DOI: 10.1055/s-0041-1729856]
  83. Pengo V, Bison E, Banzato A, Zoppellaro G, Jose SP, Denas G (2017) Lupus anticoagulant testing: Diluted Russell Viper Venom Time (dRVVT). Methods Mol Biol 1646:169–176. https://doi.org/10.1007/978-1-4939-7196-1_14 [DOI: 10.1007/978-1-4939-7196-1_14]
  84. Moore GW (2023) Lupus anticoagulant testing: Taipan snake venom time with ecarin time as confirmatory test. In: Favaloro EJ, Gosselin RC (eds) Hemostasis and thrombosis: methods and protocols, Methods in molecular biology. Springer, New York, pp 263–274. https://doi.org/10.1007/978-1-0716-3175-1_16
  85. Moore GW (2023) Lupus anticoagulant testing: Dilute Prothrombin Time (dPT). In: Favaloro EJ, Gosselin RC (eds) Hemostasis and thrombosis: methods and protocols, Methods in molecular biology. Springer, New York, pp 275–288. https://doi.org/10.1007/978-1-0716-3175-1_17
  86. Gosselin RC (2023) An acute need inspiration: autoneutralization of lupus anticoagulants in affected prothrombin times (PT) and activated partial thromboplastin times (APTT). In: Favaloro EJ, Gosselin RC (eds) Hemostasis and thrombosis: methods and protocols, Methods in molecular biology. Springer, New York, pp 289–295. https://doi.org/10.1007/978-1-0716-3175-1_18

MeSH Term

Female
Humans
Pregnancy
Antibodies, Antiphospholipid
Antiphospholipid Syndrome
beta 2-Glycoprotein I
Lupus Coagulation Inhibitor
Placenta

Chemicals

Antibodies, Antiphospholipid
beta 2-Glycoprotein I
Lupus Coagulation Inhibitor
Journal Article Review
Article has an altmetric score of 3

Word Cloud

Created with Highcharts 10.0.0aPLAntiphospholipidantibodiesAPSlaboratoryassaysantibodysyndromevariousassociatedwelltestingcriteriaLaboratoryrepresentgroupautoantibodiesdirectedphospholipidsmayarisenumberautoimmuneconditionsantiphospholipidbestrecognizedcandetectedessentiallycomprisingsolid-phaseimmunological"liquid-phase"clottingidentifyingso-calledlupusanticoagulantsLAadversepathologiesincludingthrombosisplacental/fetalmorbiditymortalitytypepresentpatternreactivityvariouslyseveritypathologyThusindicatedhelpassessfutureriskeventsrepresentingcertain"classification"alsousedsurrogatesdiagnosticcurrentchapteroverviewstestsavailablemeasurepotentialclinicalutilityOverviewTestingAntibodiesDiagnosticsLupusanticoagulant

Similar Articles

Cited By